PRESS RELEASE published on 11/05/2024 at 12:56, 1 year ago Original-Research: Alexanderwerk AG (von GSC Research GmbH): Kaufen GSC Research GmbH stuft Alexanderwerk AG hoch und erhöht Kursziel auf 23,00 Euro. Positives erstes Halbjahr 2024 trotz Umfeldschwierigkeiten. Solide Bilanzverhältnisse und attraktive Ausschüttungsrendite von 6,8 Prozent GSC Research GmbH Kursziel Erhöht Alexanderwerk AG Halbjahreszahlen 2024 Ausschüttungsrendite
PRESS RELEASE published on 07/10/2024 at 14:06, 1 year 4 months ago Original-Research: Alexanderwerk AG (von GSC Research GmbH): Kaufen GSC Research GmbH stuft Alexanderwerk AG positiv ein, nachdem das Geschäftsjahr 2023 deutlich über den Erwartungen abschloss. Analysen und Studien zum Unternehmen verfügbar Kursziel GSC Research GmbH Geschäftszahlen 2023 Analyse Alexanderwerk AG
PRESS RELEASE published on 05/26/2023 at 08:01, 2 years 6 months ago Original-Research: Alexanderwerk AG (von GSC Research GmbH): Kaufen
Published on 12/05/2025 at 02:35, 4 hours 44 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 19 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 14 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 19 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 19 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 49 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 28 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 54 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 4 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 4 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 19 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 19 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 34 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 34 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
